2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Available
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
1
Expanded_access
1
Sponsor
Cancer Type
Lymphoid
2
Conditions
Leukemia, Myeloid, Acute
17
Leukemia, Myelomonocytic, Acute
11
Leukemia, Monocytic, Acute
11
Leukemia, Megakaryoblastic, Acute
11
Leukemia, Erythroblastic, Acute
11
Breast Neoplasms
11
Congenital Abnormalities
9
Leukemia
7
Glioblastoma
7
Recurrence
6
Pancreatic Neoplasms
6
Multiple Myeloma
5
Leukemia, Myelomonocytic, Chronic
5
Leukemia, Eosinophilic, Acute
5
Leukemia, Basophilic, Acute
5
Gliosarcoma
5
Carcinoma, Non-Small-Cell Lung
5
Anemia, Refractory, with Excess of Blasts
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Breast Neoplasms, Male
4
Brain Neoplasms
4
Blast Crisis
4
Urinary Bladder Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
3
Thyroid Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Neuroblastoma
3
Melanoma
3
Interventions
Cyclophosphamide
45
Prednisone
31
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
29
Vincristine
28
Doxorubicin
27
Etoposide
22
romidepsin
20
Gemcitabine
18
Lenalidomide
16
10-propargyl-10-deazaaminopterin
16
fludarabine phosphate
15
Whole-Body Irradiation
15
Peripheral Blood Stem Cell Transplantation
14
Brentuximab Vedotin
13
Azacitidine
13
Mycophenolic Acid
12
Dexamethasone
10
Cyclosporine
10
Bortezomib
10
Alemtuzumab
10
Rituximab
8
fludarabine
7
belinostat
7
Methotrexate
6
Cytarabine
6
Busulfan
6
Bendamustine Hydrochloride
6
pembrolizumab
5
denileukin diftitox
5
Nivolumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell, Peripheral
×
tipifarnib
×
Clear all
NCT04809233
2025-06-04
Expanded Access to Tipifarnib
Kura Oncology, Inc.
Available
NCT02464228
2024-06-26
PTCL
Kura Oncology, Inc.
Phase 2
Completed
65 enrolled
16 charts